Targos, WuXi Collaborate on Cancer Biomarkers | GenomeWeb

NEW YORK (GenomeWeb) – Targos will provide its expertise, biomarker services, and quality standards to support WuXi PharmaTech's bioanalytical work for pharmaceutical customers as part of a biomarker collaboration announced today by the companies.

Targos and WuXi will focus on validating and analyzing clinical tissue biomarkers in cancer, they said, adding Targos is providing training and education to help pathologists and histotechnologists produce accurate, objective, and reproducible diagnostic results.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.